Humalutin (177Lu-DOTA-NNV003) / Thor Medical - LARVOL DELTA

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. (PubMed, PLoS One) - "The cytotoxic effect of the combination of the PARP inhibitor olaparib and the β-emitting radioimmunoconjugate 177Lu-NNV003 was synergistic in the majority of tested lymphoma cell lines."

IO biomarker • Journal • Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin in Combination with the PARP-inhibitor Olaparib (PRNewswire) - "Nordic Nanovector ASA...announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL)....The combination of Humalutin® and olaparib was found to be synergistic or conditionally synergistic leading to cell death in 6 of 7 NHL cell lines (diffuse large B cell lymphoma and mantle cell lymphoma). Where the combination was conditionally synergistic (i.e. both synergistic and antagonistic), the effect was dependent on the concentration of each drug, showing the importance of optimising the parameters for further studies....The authors concluded that further in vivo studies evaluating the anti-tumour effect of the combination of radioimmunotherapies, including Humalutin®, and PARP inhibition are warranted."

Clinical data • Diagnostic • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003. (PubMed, Eur J Nucl Med Mol Imaging) - "Lu-NNV003 had a significant anti-tumour effect and a favourable toxicity profile. These results warrant further clinical testing in patients with CD37-expressing B cell malignancies."

Journal • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nordic Nanovector awarded NOK 12 million in funding from the Norwegian Research Council to advance Alpha37, a targeted alpha therapy for B-cell cancers (PRNewswire) - “Nordic Nanovector ASA…announces that its research and development project Nanoyield has received a non-dilutive funding of NOK 12 million (USD 1.3 million) from the Norwegian Research Council (Forskningsrådet). The Nanoyield project is aimed at optimising the production yield of Nordic Nanovector's CD37-targeting antibody NNV003….The project will be conducted in partnership with SINTEF Biotechnology (Trondheim, Norway), one of Europe's largest independent research institutes.”

Financing • Licensing / partnership